This Article  • References  • Full text PDF  • Reply to article  • Send to a friend  • Save in My Folder  • Save to citation manager  • Permissions  Citing Articles  • Citation map  • Citing articles on HighWire  • Citing articles on Web of Science (102)  • Contact me when this article is cited  Related Content  • Similar articles in this journal  Social Bookmarking   What's this?

Mark Wilkerson, MD; Marshall Cyrlin, MD; Erik A. Lippa, MD, PhD; Donna Esposito, MD; Denise Deasy, MS; Deborrah Panebianco, MS; Roselyn Fazio; Michael Yablonski, MD; M. Bruce Shields, MD

Arch Ophthalmol. 1993;111(10):1343-1350.

Abstract
Objective
To investigate the activity and local and systemic safety of the topical carbonic anhydrase inhibitor, dorzolamide hydrochloride.

Design
Four-week, double-masked, randomized, placebo-5controlled, parallel, three-center study.

Setting
Referral centers.

Patients
Forty-eight patients with bilateral open angle glaucoma or ocular hypertension and intraocular pressure (IOP) greater than 22 mm Hg entered the study. Two of 28 patients receiving dorzolamide and two of 20 patients receiving placebo were withdrawn due to adverse experiences.

Intervention
Dorzolamide (2%) or placebo to each eye three times daily for 4 weeks.

Main Outcome Measures
Diurnal IOP curves; ophthalmologic evaluations including corneal ultrasound pachymetry and endothelial cell count; and systemic evaluations including vital signs, blood chemistries, complete blood cell counts, urinalysis, electrocardiogram, and drug and carbonic anhydrase activity levels in red blood cells.

Results
Mean IOP at morning trough (8 AM) decreased from 27.1 mm Hg at baseline to 23.5 mm Hg on day 29 with dorzolamide (–13.3%) compared with a decrease from 27.1 mm Hg to 26.4 mm Hg with placebo (–2.3%). Peak activity occurred 2 hours after administration, with IOP decreasing from 26.8 mm Hg at baseline to 21.8 mm Hg on day 29 with dorzolamide (–18.4%) vs 26.1 mm Hg to 25.5 (–2.4%) with placebo. Mean corneal thickness was slightly increased for the dorzolamide-treated group compared with the placebo-treated group (0.009 mm vs 0.001 mm, respectively, P<.05) and changes in endothelial cell counts were similar (–24 cells/mm² vs –27 cells/mm², respectively, P>.25). Mean carbonic anhydrase isoenzyme II activity in red blood cells decreased to 21% of baseline in dorzolamide-treated patients. There were no clinically significant differences in ocular or laboratory parameters between the dorzolamide and placebo groups.

Conclusions
Dorzolamide demonstrated significant IOP lowering activity over 4 weeks. It was well tolerated and there were no clinically significant changes in ocular or systemic safety parameters.

Author Affiliations
From the Department of Ophthalmology, Duke University, Durham, NC (Drs Wilkerson and Shields); Eye Research Institute, Oakland University, Rochester, Mich (Dr Cyrlin); Clinical Research and Biostatistics, Merck Research Laboratories, West Point, Pa (Dr Lippa and Mss Deasy and Panebianco); Department of Ophthalmology, Cornell University, New York, NY (Drs Esposito and Yablonski); and Franklin Eye Consultants, Southfield, Mich (Dr Cyrlin and Ms Fazio).

CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    Twitter     What's this?

THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES

Role of Carbonic Anhydrase IV in Corneal Endothelial HCO3- Transport
Sun et al.
IOVS 2008;49:1048-1055.
ABSTRACT | FULL TEXT  

Effect of Dorzolamide Hydrochloride on Central Corneal Thickness in Humans With Cornea Guttata
Wirtitsch et al.
Arch Ophthalmol 2007;125:1345-1350.
ABSTRACT | FULL TEXT  

Brimonidine purite 0.15% versus dorzolamide 2% each given twice daily to reduce intraocular pressure in subjects with open angle glaucoma or ocular hypertension
Sharpe et al.
Br J Ophthalmol 2004;88:953-956.
ABSTRACT | FULL TEXT  

Short-term Effect of Dorzolamide Hydrochloride on Central Corneal Thickness in Humans With Cornea Guttata
Wirtitsch et al.
Arch Ophthalmol 2003;121:621-625.
ABSTRACT | FULL TEXT  

Inhibition of Carbonic Anhydrase Activity in Cultured Bovine Corneal Endothelial Cells by Dorzolamide
Srinivas et al.
IOVS 2002;43:3273-3278.
ABSTRACT | FULL TEXT  

Periorbital dermatitis as a side effect of topical dorzolamide
Delaney et al.
Br J Ophthalmol 2002;86:378-380.
ABSTRACT | FULL TEXT  

A comparison of latanoprost and dorzolamide in patients with glaucoma and ocular hypertension: a 3 month, randomised study
O'Donoghue and the UK and Ireland Latanoprost Study Group
Br J Ophthalmol 2000;84:579-582.
ABSTRACT | FULL TEXT  

Nephrolithiasis With Dorzolamide
Carlsen et al.
Arch Ophthalmol 1999;117:1087-1088.
FULL TEXT  

A Double-Masked, Randomized, 1-Year Study Comparing the Corneal Effects of Dorzolamide, Timolol, and Betaxolol
Lass et al.
Arch Ophthalmol 1998;116:1003-1010.
ABSTRACT | FULL TEXT  

Aqueous Humor Flow in Human Eyes Treated With Dorzolamide and Different Doses of Acetazolamide
Larsson and Alm
Arch Ophthalmol 1998;116:19-24.
ABSTRACT | FULL TEXT  

Topical 2.0% Dorzolamide vs Oral Acetazolamide for Prevention of Intraocular Pressure Rise After Neodymium:YAG Laser Posterior Capsulotomy
Ladas et al.
Arch Ophthalmol 1997;115:1241-1244.
ABSTRACT  

Central Corneal Thickness in Normal, Glaucomatous, and Ocular Hypertensive Eyes
Herndon et al.
Arch Ophthalmol 1997;115:1137-1141.
ABSTRACT  

Comparison of Dorzolamide and Acetazolamide as Suppressors of Aqueous Humor Flow in Humans
Maus et al.
Arch Ophthalmol 1997;115:45-49.
ABSTRACT  

A Double-Masked, Randomized 1-Year Study Comparing Dorzolamide (Trusopt), Timolol, and Betaxolol
Strahlman et al.
Arch Ophthalmol 1995;113:1009-1016.
ABSTRACT